Senti Biosciences Holdings, Inc. (SNTI) · Oct 13, 2026 · Acquisition

Senti Biosciences merger vote delayed as support remains uncertain

Vote adjourned — Meeting reconvened October 15 after no business was conducted

Senti Biosciences adjourned its annual meeting to solicit more votes for the Celadon-backed merger, pushing the decision to October 15.

Senti is a cash-constrained clinical-stage biotech trying to transfer substantially all of its existing business and lead SENTI-202 program to a Celadon-controlled private company, while leaving the public entity focused on its Regulator Dial platform and a smaller set of early-stage programs.

The merger vote did not fail, but it was not completed. Despite having a quorum, Senti adjourned the October 8 meeting specifically to seek additional support for the merger proposal. That is a modest negative signal versus the standing expectation that a scheduled shareholder vote would produce a result, because approval is still unresolved; however, the filing gives no vote tally and does not say the proposal is losing.

This changes timing more than substance. The merger, its proposed transfer of the pipeline, and the shareholder vote were already public, so the new information is mainly that Senti needs another week to secure approval—not a change to the transaction terms or the post-merger business plan. The proposals and record date remain unchanged.

Bottom line: The filing keeps the Celadon-backed merger alive but exposes execution uncertainty around shareholder approval. It matters as a delay and a mild warning sign, not as a rejection or a revised deal.

What to watch next

Revised annual meeting and merger vote, October 15

Original filing on SEC EDGAR

More Senti Biosciences Holdings, Inc. news

Senti Biosciences merger vote delayed as support remains uncertain | SNTI Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.